Immunoreconstitution by Bone Marrow Transplantation Decreases Lymphoproliferative Malignancies in Wiskott-Aldrich and Severe Combined Immune Deficiency Syndromes

  • Steven M. L. Neudorf
  • Alexandra H. Filipovich
  • John H. Kersey


Data linking immunodeficient individuals to a high incidence of malignancy has been collected through the analysis of outcomes in renal allograft recipients (1) and patients with naturally occurring immunodeficiency states such as severe combined immune deficiency (SCID), Wiskott-Aldrich syndr ome (WAS) and ataxia telangiectasia (2–4). The mechanisms involved in the pathogenesis of malignancy in patients with naturally occurring or acquired immunodeficiencies are poorly understood. In large part this is due to the heterogeneity in the scope and severity of immune deficiency in these patients. In addition, some patients are exposed to potentially oncogenic agents, such as Epstein-Barr virus (EBV), that may influence the development of malignancy. Despite the complexity of these patients, certain aspects of the relationship between naturally occurring immune deficiency and malignancy can be studied. Many patients with SCID and WAS have been successfully immunoreconstituted by bone marrow transplantation (BMT). Therefore, it has become possible to ask whether immunoreconstitution prevents the development of malignancy in these patients. This chapter addresses this question by analyzing cases of malignancy in immunodeficient individuals that have undergone either BMT or thymus transplantation. These data will be compared to previously reported cases of malignancies in untransplanted immunodeficient patients.


Post Transplant Ataxia Telangiectasia Severe Combine Immunodeficiency Severe Combine Immune Deficiency Renal Allograft Recipient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Penn, I. Malignancies associated with immunosuppressive or cytotoxic therapy. Surgery, 83:294, 1978.Google Scholar
  2. 2.
    Kersey, J., Spector, B., and Good, R. Primary immunodeficiency diseases and cancer: the Immunodeficiency-Cancer Registry. Int. J. Cancer, 12:333, 1973.PubMedCrossRefGoogle Scholar
  3. 3.
    Filipovich, A.H., Zerbe, D., Spector, B., and Kersey, J. Lymphomas in persons with naturally occurring immunodeficiency disorders. In: I.T. Magrath (ed.), The Influence of the Environment on Leukemia and Lymphoma Subtypes. New York: Raven Press, 1983.Google Scholar
  4. 4.
    Spector, B.D., Perry, G., and Kersey, J.H. Genetically determined immunodeficiency diseases (GDID) and malignancy: report from the Immunodeficiency-Cancer Registry. Clin. Immunol. Immunopathol., 11:12, 1978.PubMedCrossRefGoogle Scholar
  5. 5.
    Bortin, M. and Rimm, A. Severe combined immunodeficiency disease. Characterization of the disease and results of transplantation. J. Am. Med. Assoc, 238:591, 1977.CrossRefGoogle Scholar
  6. 6.
    Hong, R. Present and future status of thymus transplantation. Ann. Clin. Res., 13:350, 1981.PubMedGoogle Scholar
  7. 7.
    Borzy, M.S., Hong, R., Horowitz, S.D., Gilbert, E., Kaurman, D., De Mendonca, W., Oxelius, V.A., Dictor, M., and Pachman, L. Fatal lymphoma after transplantation of cultured thymus in children with combined immunodeficiency disease. N. Engl. J. Med., 301:565, 1979.PubMedCrossRefGoogle Scholar
  8. 8.
    Frizzera, G., Rosai, J., Dehner, L., Spector, B.D., and Kersey, J.H. Lymphoreticular disorders in primary immunodeficiencies: new findings based on an up-to-date histologic classification of 35 cases. Cancer, 46:692, 1980.PubMedCrossRefGoogle Scholar
  9. 9.
    Kapoor, N., Kirkpatrick, D., Blaese, R., Oleske, J., Hilgartner, M., Changanti, R., Good, R., and O’Reilly, R. Reconstitution of normal megakaryocytopoiesis and immunologic functions in Wiskott-Aldrich syndrome by marrow transplantation following myeloablation and immunosuppression with busulfan and cyclophosphamide. Blood, 57:692, 1981.PubMedGoogle Scholar
  10. 10.
    Bach, H.F., Albertini, R. J., Joo, P., Anderson, J.L., and Bortin, M.M. Bone marrow transplantation in a patient with the Wiskott-Aldrich syndrome. Lancet, ii:1364, 1968.CrossRefGoogle Scholar
  11. 11.
    August, C.S., Hathaway, W.W., Githens, J.H., Pearlman, D., Mcintosh, K., and Favara, B. Improved platelet function following bone marrow transplantation in an infant with Wiskott-Aldrich syndrome. J. Pediat., 82:58, 1973.PubMedCrossRefGoogle Scholar
  12. 12.
    Meuwissen, H.J., Kieserman, E.G., Taft, B., Pollara, B., and Pickering, R.J. Marrow transplantation in Wiskott-Aldrich syndrome: T cell engraftment with cyclophosphamide. Complete engraftment with total body irradiation. Pediat. Res., 12:483, 1978.CrossRefGoogle Scholar
  13. 13.
    Parkman, R., Rappaport, D., Geha, R., Cassady, R., Levey, R., Nathan, D.G., Belli, J., and Rosen, F. Complete correction of the Wiskott-Aldrich syndrome by allogeneic bone marrow transplantation. N. Engl. J. Med., 298:921, 1978.PubMedCrossRefGoogle Scholar
  14. 14.
    Hanto, D., Sakamoto, K., Purtilo, D.T., Simmons, R., and Najarian, J. The Epstein-Barr virus in the pathogenesis of post transplant lymphoproliferative disorders. Surgery, 90:204, 1981.PubMedGoogle Scholar
  15. 15.
    Thestrup-Pedersen, K., Esmann, V., Jensen, J.R., Hastrup, J., Thorling, K., Saemundsen, A.K., Bisballe, S., Oallesen, G., Madsen, M., Grazia-Masucci, M., and Emberg, I. Epstein-Barr virus-induced lymphoproliferative disorder converting to fatal Burkitt-like lymphoma in a boy with interferon inducible chromosomal defect. Lancet, ii:997, 1980.CrossRefGoogle Scholar
  16. 16.
    Taylor, A., Harnden, D., Arlett, C., Harcourt, S., Lehmann, A., Stevens, S., and Bridges, B. Ataxia telangiectasia: a human mutation with abnormal radiation sensitivity. Nature, 258:427, 1975.PubMedCrossRefGoogle Scholar
  17. 17.
    Filipovich, A.H. and Spector, B.D. Immunodeficiency (ID) as a susceptibility factor for malignancy in ataxia telangiectasia (AT): report from the Immunodeficiency-Cancer Registry (ICR). Pediat. Res., 15(4):806, 1981.Google Scholar
  18. 18.
    Tsoi, M. Immunological mechanisms of graft-versus-host disease in man. Transplantation, 33:459, 1982.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1984

Authors and Affiliations

  • Steven M. L. Neudorf
    • 1
  • Alexandra H. Filipovich
    • 1
  • John H. Kersey
    • 1
  1. 1.Department of Pediatrics and Laboratory MedicineUniversity of MinnesotaMinneapolisUSA

Personalised recommendations